Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06007846 · ClinicalTrials.gov registry record · Phase 2
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
A Phase 2 study of Hepatocellular Carcinoma and Cirrhosis, sponsored by Inova Health Care Services.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 2
- Study locations
NCT06007846: Recruiting Phase 2 study of Hepatocellular Carcinoma and Cirrhosis, sponsored by Inova Health Care Services.
NCT06007846 is a Phase 2 study of Hepatocellular Carcinoma and Cirrhosis that is actively recruiting participants, run by Inova Health Care Services. The registered enrollment target is 12 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06007846, a Phase 2 study of Hepatocellular Carcinoma and Cirrhosis, is actively recruiting participants, sponsored by Inova Health Care Services.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a single-site prospective study to describe efficacy endpoints of single agent memantine in patients with unresectable, locally advanced, or metastatic HCC otherwise not deemed candidates for intensive systemic therapy. In addition to the primary endpoint and multiple secondary efficacy endpoints, we will describe changes in quality of life on treatment over time.
Primary Outcome
The response and progression will be evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) guideline version 1.1. The progression of the disease is defined as at least a 20% increase in the sum of the Longest Diameter LD of target lesions, taking the smallest sum LD recorded as reference since the treatment started or the appearance of one or more new lesions or death due to disease without objective evidence of progression.
Conditions Studied
Interventions
- DRUG Namenda
Study Locations (2)
Virginia
- Inova Schar Cancer Institute - Fairfax
- Inova Health Care Service - Falls Church
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2023-07-31 |
| Est. Completion | 2026-08-31 |
| Phase | Phase 2 |
What NCT06007846 shows while recruiting
NCT06007846 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Namenda is the first listed.
NCT06007846 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT06007846 about?
NCT06007846 is a clinical study titled "A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer". This is a single-site prospective study to describe efficacy endpoints of single agent memantine in patients with unresectable, locally advanced, or metastatic HCC otherwise not deemed candidates for intensive systemic therapy. In addition to the primary endpoint and multiple secondary efficacy endp...
What is the current status of trial NCT06007846?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2023-07-31. Estimated completion is 2026-08-31.
What conditions does trial NCT06007846 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma, Cirrhosis.
What interventions are being tested in trial NCT06007846?
The interventions under investigation include: Namenda (DRUG).
Who is sponsoring clinical trial NCT06007846?
This trial is sponsored by Inova Health Care Services, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06007846 being conducted?
This trial has 2 study locations across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06007846's enrollment target sits among peer trials
12 137th of 145 higher than 7 of 145 other Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
RECRUITING · Phase 2
-
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
RECRUITING · Phase 2
-
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
RECRUITING · Phase 2
-
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI